8-K filing — Jaguar Health, Inc. (JAGX)
Filed: 2026-11-16 AccNo: 0001193125-26-462345 Size: 212 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Jaguar Health announced its financial results for the third quarter of 2026, highlighting a significant reduction in net loss and a strategic focus on rare disease development.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-16 AccNo: 0001193125-26-462345 Size: 212 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Jaguar Health, Inc. has provided forward-looking guidance regarding the scheduled filing of its Form 10-Q for the third quarter of 2026 and an associated investor webcast.
Jaguar Health, Inc. announced that stockholders approved all six proposals submitted during the company's special meeting held on November 6, 2026.
Jaguar Health has filed an SEC Form S-3 to register up to $75 million in securities and announced the completion of enrollment for its pivotal crofelemer trial in microvillus inclusion disease (MVID).
Alcoa shares rose after Q3 earnings beat estimates; Rubico and others surged, while Nuburu, Jaguar Health and other stocks fell premarket.